<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors report hematologic and cytogenetic data on 19 patients treated with allogeneic bone marrow transplantation (BMT) for severe <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e>: 8 patients with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, 6 with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, 3 with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 1 with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>, and 1 with <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia major</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Cytogenetic assays were performed on marrow cells before conditioning, 30 days after BMT, and at subsequent times </plain></SENT>
<SENT sid="2" pm="."><plain>The authors discuss the role of cytogenetic studies in the evaluation of bone marrow engraftment, leukemic transformation of the graft, and disease relapse </plain></SENT>
</text></document>